Selected article for: "influenza virus and sore throat"
Author: He, Jiayang; Li, Zhengtu; Huang, Wanyi; Guan, Wenda; Ma, Hongxia; Yang, Zi feng; Wang, Xinhua
Title: Efficacy and safety of Chou-Ling-Dan granules in the treatment of seasonal influenza via combining Western and traditional Chinese medicine: protocol for a multicentre, randomised controlled clinical trial
  • Document date: 2019_4_2
    • ID: vn9e5nm3_67
    Snippet: The primary and secondary outcomes and safety indicators will be used to evaluate the efficacy and The clinical medicines used for the treatment and prevention of influenza are mainly M2 ion 77 channel blockers (for example, amantadine and rimantadine) and neuraminidase (NA) inhibitors 78 (for example, oseltamivir and zanamivir) 6,7 . Amantadine, however, is prone to drug resistance and 79 is only effective against the influenza A virus 8 . In ad.....
    Document: The primary and secondary outcomes and safety indicators will be used to evaluate the efficacy and The clinical medicines used for the treatment and prevention of influenza are mainly M2 ion 77 channel blockers (for example, amantadine and rimantadine) and neuraminidase (NA) inhibitors 78 (for example, oseltamivir and zanamivir) 6,7 . Amantadine, however, is prone to drug resistance and 79 is only effective against the influenza A virus 8 . In addition, the treatment efficiency of amantadine is lower than that of the NA inhibitors. Therefore, amantadine is not recommended routinely for the antibacterial, anti-inflammatory and clearing heat-toxicity effects. The root, or the whole plant, has 110 been widely been used to treat colds, sore throat, bronchitis, malaria and other diseases 18 . system. To develop CLD into a targeted drug with less side effects that can be widely used in the 130 prevention and treatment of influenza, an in-depth study needs to be conducted.

    Search related documents:
    Co phrase search for related documents
    • channel blocker and rimantadine amantadine: 1
    • CLD develop and depth study: 1
    • CLD develop and influenza prevention treatment: 1
    • CLD develop and prevention treatment: 1
    • clinical medicine and conduct need: 1
    • clinical medicine and drug resistance: 1, 2, 3, 4, 5, 6
    • clinical medicine and prevention treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • conduct need and prevention treatment: 1
    • depth study and influenza prevention treatment: 1
    • depth study and prevention treatment: 1, 2, 3, 4, 5
    • drug resistance and influenza prevention treatment: 1, 2
    • drug resistance and prevention treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • drug resistance and rimantadine amantadine: 1, 2, 3, 4, 5
    • heat toxicity and prevention treatment: 1, 2, 3
    • influenza prevention treatment and prevention treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • influenza prevention treatment and rimantadine amantadine: 1, 2, 3, 4, 5
    • influenza prevention treatment and safety secondary primary outcome: 1
    • NA inhibitor and rimantadine amantadine: 1, 2
    • prevention treatment and rimantadine amantadine: 1, 2, 3, 4, 5, 6, 7, 8, 9